Multistep resistance development studies of ceftaroline in gram-positive and -negative bacteria

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 5, 2011, Pages 2344-2351

  Clark, Catherine ^a   McGhee, Pamela ^a   Appelbaum, Peter C ^a   Kosowska Shick, Klaudia ^a  

^a PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; AZITHROMYCIN; BETA LACTAMASE; CEFTAROLINE; CEFTRIAXONE; LINEZOLID; MOXIFLOXACIN; PENICILLIN G; TIGECYCLINE;

ANTIBIOTIC RESISTANCE; ARTICLE; ENTEROCOCCUS FAECALIS; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HAEMOPHILUS INFLUENZAE; KLEBSIELLA PNEUMONIAE; MINIMUM INHIBITORY CONCENTRATION; MORAXELLA CATARRHALIS; NONHUMAN; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE; STREPTOCOCCUS PYOGENES;

ANTI-BACTERIAL AGENTS; CEPHALOSPORINS; ENTEROCOCCUS FAECALIS; GRAM-NEGATIVE BACTERIA; GRAM-POSITIVE BACTERIA; HAEMOPHILUS INFLUENZAE; KLEBSIELLA PNEUMONIAE; MICROBIAL SENSITIVITY TESTS; MORAXELLA (BRANHAMELLA) CATARRHALIS; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE; STREPTOCOCCUS PYOGENES;

EID: 79955549518     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01602-10     Document Type: Article

References (65)

1. Albrich, W. C., D. L. Monnet, and S. Harbarth. 2004. Antibiotic selection pressure and resistance in Streptococcus pneumoniae and Streptococcus pyogenes. Emerg. Infect. Dis. 10:514-517.
2. Appelbaum, P. C., and B. Bozdogan. 2004. Vancomycin resistance in Staphylococcus aureus. Clin. Lab. Med. 24:381-402.
3. Bogdanovich, T., et al. 2006. Activities of ceftobiprole, a novel broad-spectrum cephalosporin, against Haemophilus influenzae and Moraxella catarrhalis. Antimicrob. Agents Chemother. 50:2050-2057.
4. Bogdanovich, T., et al. 2006. Activity of LBM415 compared to those of 11 other agents against Haemophilus species. Antimicrob. Agents Chemother. 50:2323-2329.
5. Bozdogan, B., and P. C. Appelbaum. 2004. Macrolide resistance in streptococci and Haemophilus influenzae. Clin. Lab. Med. 24:455-475.
6. Bozdogan, B., D. Esel, C. Whitener, F. A. Browne, and P. C. Appelbaum. 2003. Antibacterial susceptibility of a vancomycin-resistant Staphylococcus aureus strain isolated at the Hershey Medical Center. J. Antimicrob. Chemother. 52:864-868.
7. Bradford, P. A., et al. 1997. Imipenem resistance in Klebsiella pneumoniae is associated with the combination of ACT-1, a plasmid-mediated AmpC β-lactamase, and the foss of an outer membrane protein. Antimicrob. Agents Chemother. 41:563-569.
8. Brown, S. D., and M. M. Traczewski. 2009. In vitro antimicrobial activity of a new cephalosporin, ceftaroline, and determination of quality control ranges for MIC testing. Antimicrob. Agents Chemother. 53:1271-1274.
9. Browne, F. A., et al. 2003. Antipneumococcal activity of DK-507k, a new quinolone, compared with the activities of 10 other agents. Antimicrob. Agents Chemother. 47:3815-3824.
10. Centers for Disease Control and Prevention. 2002. Vancomycin-resistant Staphylococcus aureus-Pennsylvania, 2002. MMWR Morb. Mortal. Wkly. Rep. 51:902. http://www.cdc.gov/mmwr//preview/mmwrhtml/mm5126a1.htm.
11. Chambers, H. F., and C. Miick. 1992. Characterization of penicillin-binding protein 2 of Staphylococcus aureus: deacylation reaction and identification of two penicillin-binding peptides. Antimicrob. Agents Chemother. 36:656-661.
12. Clark, C., et al. 2009. Antistaphylococcal activity of dihydrophthalazine antifolates, a family of novel antibacterial drugs. Antimicrob. Agents Chemother. 53:1353-1361.
13. Clark, C., et al. 2004. In vitro selection of resistance in Haemophilus influenzae by 4 quinolones and 5 β-lactams. Diagn. Microbiol. Infect. Dis. 49:31-36.
14. Clark, C., et al. 2008. In vitro activity of DC-159a, a new broad-spectrum fluoroquinolone, compared with that of other agents against drug-susceptible and -resistant pneumococci. Antimicrob. Agents Chemother. 52:77-84.
15. Clark, C. L., K. Kosowska-Shick, L. M. Ednie, and P. C. Appelbaum. 2007. Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies. Antimicrob. Agents Chemother. 51:4196-4201.
16. Clinical and Laboratory Standards Institute. 2009. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard M07-A8; 8th ed. Clinical Laboratory Standards Institute, Wayne, PA.
17. Clinical and Laboratory Standards Institute. 2010. Performance standards for antimicrobial susceptibility testing. Approved standard M100-S20; 20th informational supplement. Clinical and Laboratory Standards Institute, Wayne, PA.
18. Davies, T. A., et al. 2000. Activities and postantibiotic effects of gemifloxacin compared to those of 11 other agents against Haemophilus influenzae and Moraxella catarrhalis. Antimicrob. Agents Chemother. 44:633-639.
19. el Amin, N., S. Jalal, and B. Wretlind. 1999. Alterations in GyrA and ParC Associated with Fluoroquinolone Resistance in Enterococcus faecium. Antimicrob. Agents Chemother. 43:947-949.
20. Fenoll, A., et al. 2008. In vitro activity of ceftaroline against Streptococcus pneumoniae isolates exhibiting resistance to penicillin, amoxicillin, and cefotaxime. Antimicrob. Agents Chemother. 52:4209-4210.
21. File, T. M., Jr., J. S. Tan, and J. F. Plouffe. 1998. The role of atypical pathogens: Mycoplasma pneumoniae, Chlamydia pneumoniae, and Legionella pneumophila in respiratory infection. Infect. Dis. Clin. N. Am. 12:569-592, vii.
22. Ge, Y., D. Biek, G. H. Talbot, and D. F. Sahm. 2008. In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States. Antimicrob. Agents Chemother. 52:3398-3407.
23. Georgopapadakou, N. H. 1993. Penicillin-binding proteins and bacterial resistance to β-lactams. Antimicrob. Agents Chemother. 37:2045-2053.
24. Hasegawa, K., et al. 2004. Rapidly increasing prevalence of beta-lactamase-nonproducing, ampicillin-resistant Haemophilus influenzae type b in patients with meningitis. Antimicrob. Agents Chemother. 48:1509-1514.
25. Higashi, Y., A. Wakabayashi, Y. Matsumoto, Y. Watanabe, and A. Ohno. 1999. Role of inhibition of penicillin binding proteins and cell wall crosslinking by β-lactam antibiotics in low- and high-level methicillin resistance of Staphylococcus aureus. Chemotherapy 45:37-47. (Pubitemid 29027534)
26. Jacobs, M. R., D. Felmingham, P. C. Appelbaum, and R. N. Gruneberg. 2003. The Alexander Project 1998-2000: susceptibility of pathogens isolated from community-acquired respiratory tract infection to commonly used antimicrobial agents. J. Antimicrob. Chemother. 52:229-246.
27. Johnson, A. W., et al. 2008. Etiologic agents and outcome determinants of community-acquired pneumonia in urban children: a hospital-based study. J. Natl. Med. Assoc. 100:370-385.
28. Jones, M. E., et al. 2002. Apparent plateau in beta-lactamase production among clinical isolates of Haemophilus influenzae and Moraxella catarrhalis in the United States: results from the LIBRA Surveillance initiative. Int. J. Antimicrob. Agents 19:119-123.
29. Jones, R. N., T. R. Fritsche, H. S. Sader, and J. E. Ross. 2007. LEADER surveillance program results for 2006: an activity and spectrum analysis of linezolid using clinical isolates from the United States (50 medical centers). Diagn. Microbiol. Infect. Dis. 59:309-317.
30. Julian, K., et al. 2007. Characterization of a daptomycin-nonsusceptible vancomycin-intermediate Staphylococcus aureus strain in a patient with endocarditis. Antimicrob. Agents Chemother. 51:3445-3448.
31. Kanafani, Z. A., and G. R. Corey. 2009. Ceftaroline: a cephalosporin with expanded Gram-positive activity. Future Microbiol. 4:25-33.
32. Katayama, Y., H.-Z. Zhang, and H. F. Chambers. 2004. PBP 2a mutations producing very-high-level resistance to β-lactams. Antimicrob. Agents Chemother. 48:453-459.
33. Kosowska-Shick, K., et al. 2008. In vitro capability of faropenem to select for resistant mutants of Streptococcus pneumoniae and Haemophilus influenzae. Antimicrob. Agents Chemother. 52:748-752.
34. Kosowska-Shick, K., et al. 2006. Single- and multistep resistance selection studies on the activity of retapamulin compared to other agents against Staphylococcus aureus and Streptococcus pyogenes. Antimicrob. Agents Chemother. 50:765-769.
35. Kosowska-Shick, K., et al. 2007. Multistep resistance selection and postantibiotic-effect studies of the antipneumococcal activity of LBM415 compared to other agents. Antimicrob. Agents Chemother. 51:770-773.
36. Kosowska-Shick, K., L. M. Ednie, P. McGhee, and P. C. Appelbaum. 2009. Comparative antipneumococcal activities of sulopenem and other drugs. Antimicrob. Agents Chemother. 53:2239-2247.
37. Kosowska-Shick, K., et al. 2008. Incidence and characteristics of vancomycin nonsusceptible strains of methicillin-resistant Staphylococcus aureus at Hershey Medical Center. Antimicrob. Agents Chemother. 52:4510-4513.
38. Kosowska, K., et al. 2004. Activities of two novel macrolides, GW 773546 and GW 708408, compared with those of telithromycin, erythromycin, azithromycin, and clarithromycin against Haemophilus influenzae. Antimicrob. Agents Chemother. 48:4113-4119.
39. Kosowska, K., et al. 2005. Antipneumococcal activity of ceftobiprole, a novel broad-spectrum cephalosporin. Antimicrob. Agents Chemother. 49:1932-1942.
40. Leclercq, R., and P. Courvalin. 1991. Bacterial resistance to macrolide, lincosamide, and streptogramin antibiotics by target modification. Antimicrob. Agents Chemother. 35:1267-1272.
41. Locke, J. B., M. Hilgers, and K. J. Shaw. 2009. Mutations in ribosomal protein L3 are associated with oxazolidinone resistance in staphylococci of clinical origin. Antimicrob. Agents Chemother. 53:5275-5278.
42. Lutwick, L., and L. Fernandes. 2006. The other siblings: respiratory infections caused by Moraxella catarrhalis and Haemophilus influenzae. Curr. Infect. Dis. Rep. 8:215-221.
43. Matic, V., et al. 2004. Antipneumococcal activities of two novel macrolides, GW 773546 and GW 708408, compared with those of erythromycin, azithromycin, clarithromycin, clindamycin, and telithromycin. Antimicrob. Agents Chemother. 48:4103-4112.
44. McAleese, F., et al. 2005. A novel MATE family efflux pump contributes to the reduced susceptibility of laboratory-derived Staphylococcus aureus mutants to tigecycline. Antimicrob. Agents Chemother. 49:1865-1871.
45. McGee, L. 2007. The coming of age of niche vaccines? Effect of vaccines on resistance profiles in Streptococcus pneumoniae. Curr. Opin. Microbiol. 10:473-478.
46. McGee, L., et al. 2009. In vitro evaluation of the antimicrobial activity of ceftaroline against cephalosporin-resistant isolates of Streptococcus pneumoniae. Antimicrob. Agents Chemother. 53:552-556.
47. McGhee, P., et al. 2010. In vitro activity of CEM-101 against Streptococcus pneumoniae and Streptococcus pyogenes with defined macrolide resistance mechanisms. Antimicrob. Agents Chemother. 54:230-238.
48. Morikawa, Y., et al. 2004. In vitro activities of piperacillin against β-lactamase-negative ampicillin-resistant Haemophilus influenzae. Antimicrob. Agents Chemother. 48:1229-1234.
49. Morrissey, I., Y. Ge, and R. Janes. 2009. Activity of the new cephalosporin ceftaroline against bacteraemia isolates from patients with community-acquired pneumonia. Int. J. Antimicrob. Agents 33:515-519.
50. Mushtaq, S., M. Warner, Y. Ge, K. Kaniga, and D. M. Livermore. 2007. In vitro activity of ceftaroline (PPI-0903M, T-91825) against bacteria with defined resistance mechanisms and phenotypes. J. Antimicrob. Chemother. 60:300-311.
51. Nagai, K., et al. 2002. Susceptibilities to telithromycin and six other agents and prevalence of macrolide resistance due to L4 ribosomal protein mutation among 992 pneumococci from 10 central and eastern European countries. Antimicrob. Agents Chemother. 46:371-377.
52. Nagai, K., et al. 2002. Susceptibility to telithromycin in 1,011 Streptococcus pyogenes isolates from 10 central and Eastern European countries. Antimicrob. Agents Chemother. 46:546-549.
53. Parish, D., and N. Scheinfeld. 2008. Ceftaroline fosamil, a cephalosporin derivative for the potential treatment of MRSA infection. Curr. Opin. Invest. Drugs. 9:201-209.
54. Peric, M., B. Bozdogan, M. R. Jacobs, and P. C. Appelbaum. 2003. Effects of an efflux mechanism and ribosomal mutations on macrolide susceptibility of Haemophilus influenzae clinical isolates. Antimicrob. Agents Chemother. 47:1017-1022.
55. Pichichero, M. E., and J. R. Casey. 2007. Emergence of a multiresistant serotype 19A pneumococcal strain not included in the 7-valent conjugate vaccine as an otopathogen in children. JAMA 298:1772-1778.
56. Rossolini, G. M., E. Mantengoli, F. Montagnani, and S. Pollini. 2010. Epidemiology and clinical relevance of microbial resistance determinants versus anti-Gram-positive agents. Curr. Opin. Microbiol. 13:582-588.
57. Sader, H. S., T. R. Fritsche, and R. N. Jones. 2008. Antimicrobial activities of ceftaroline and ME1036 tested against clinical strains of community-acquired methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 52:1153-1155.
58. Seputiene, V., et al. 2010. Tigecycline: how powerful is it in the fight against antibiotic-resistant bacteria? Medicina (Kaunas) 46:240-248.
59. Shuel, M. L., and R. S. Tsang. 2009. Canadian β-lactamase-negative Haemophilus influenzae isolates showing decreased susceptibility toward ampicillin have significant penicillin binding protein 3 mutations. Diagn. Microbiol. Infect. Dis. 63:379-383.
60. Ubukata, K., et al. 2001. Association of amino acid substitutions in penicillin-binding protein 3 with β-lactam resistance in β-lactamase-negative ampicillin-resistant Haemophilus influenzae. Antimicrob. Agents Chemother. 45:1693-1699.
61. Van Bambeke, F., R. R. Reinert, P. C. Appelbaum, P. M. Tulkens, and W. E. Peetermans. 2007. Multidrug-resistant Streptococcus pneumoniae infections: current and future therapeutic options. Drugs 67:2355-2382.
62. Vardakas, K. Z., D. K. Matthaiou, and M. E. Falagas. 2009. Incidence, characteristics and outcomes of patients with severe community acquired-MRSA pneumonia. Eur. Respir. J. 34:1148-1158.
63. Weisblum, B. 1995. Erythromycin resistance by ribosome modification. Antimicrob. Agents Chemother. 39:577-585.
64. Wong, A., et al. 2009. Polyphyletic emergence of linezolid-resistant staphylococci in the United States. Antimicrob. Agents Chemother. 54:742-748.
65. Yokota, S.-I., Y. Ohkoshi, K. Sato, and N. Fujii. 2008. Emergence of fluoroquinolone-resistant Haemophilus influenzae strains among elderly patients but not among children. J. Clin. Microbiol. 46:361-365.